All articles tagged with #severe asthma
GSK's Exdensur (depemokimab) has been approved by the US FDA as a twice-yearly treatment for severe eosinophilic asthma in patients aged 12 and older, based on phase III trial data showing significant reduction in exacerbations and hospitalizations, with a favorable safety profile.
A landmark clinical trial funded by AstraZeneca has found that benralizumab, a monoclonal antibody treatment, can significantly reduce the need for high-dose steroid treatments in patients with severe eosinophilic asthma. The study showed that 92% of patients safely reduced their use of inhaled steroids, with over 60% no longer needing them at all. Benralizumab works by targeting and reducing inflammation-causing immune cells called eosinophils. However, the researchers caution that these results only apply to a specific type of asthma, and patients who do not respond as well to benralizumab may still require intensive steroid treatments.